We are live on ! Find out more
LSBPW

LakeShore Biopharma Warrants
LSBPW

Delisted

LSBPW was delisted on the 19th of September, 2025.

Back to rankings

28 hedge funds and large institutions have $266K invested in LakeShore Biopharma Warrants in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.46% less ownership

Funds ownership: 6.36% → 5.9% (-0.46%)

7% less funds holding

Funds holding: 30 → 28 (-2)

25% less capital invested

Capital invested by funds: $356K → $266K (-$89.3K)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
28
Holders Change
-2
Holders Change %
-6.67%
% of All Funds
0.41%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
2
Increased
2
Reduced
2
Closed
4
Calls
$33K
Puts
–
Net Calls
+$33K
Net Calls Change
-$9K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$417
2
WAM
Wolverine Asset Management
Illinois
+$40
3
CS
Clear Street
New York
+$7
4
CAC
Cowen and Company
New York
+$7

Top Sellers

Rank Fund Capital Flow
1
ICM
Ionic Capital Management
New York
-$11.3K
2
RCM
Radcliffe Capital Management
Pennsylvania
-$2.42K
3
ETH
Exos TFP Holdings
New York
-$1.62K
4
AA
AQR Arbitrage
Connecticut
-$1.49K
5
SCM
Shaolin Capital Management
Florida
-$780
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Athos Capital
Hong Kong
$67K – – –
LP
2
LMR Partners
United Kingdom
$40K – – –
VAM
3
Valliance Asset Management
Hong Kong
$28.5K – – –
SLM
4
Snow Lake Management
California
$19K – – –
Jane Street
5
Jane Street
New York
$18.9K – – –
BP
6
BFAM Partners
Hong Kong
$14.9K – – –
FC
7
Finepoint Capital
Massachusetts
$13.3K – – –
HCM
8
Highbridge Capital Management
New York
$10.8K – – –
BCL
9
Bracebridge Capital LLC
Massachusetts
$8.83K – – –
CAC
10
Cowen and Company
New York
$7.61K +$7 +221 +0.1%
QGA
11
Q Global Advisors
Texas
$5K – – –
WA
12
Whitebox Advisors
Minnesota
$4.75K – – –
Calamos Advisors
13
Calamos Advisors
Illinois
$3.96K – – –
Walleye Capital
14
Walleye Capital
New York
$3.8K – – –
SCM
15
Saba Capital Management
New York
$3.17K – – –
CF
16
Cantor Fitzgerald
New York
$2.92K – – –
SCM
17
Shaolin Capital Management
Florida
$2.9K -$780 -23,566 -24%
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$2.71K – – –
ETH
19
Exos TFP Holdings
New York
$1.9K -$1.62K -49,000 -49%
CS
20
Clear Street
New York
$1.81K +$7 +200 +0.4%
SVI
21
Strategic Vision Investment
Hong Kong
$1.48K – – –
EC
22
Elequin Capital
New York
$1.43K – – –
MC
23
Meteora Capital
Florida
$950 – – –
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$341 +$417 +12,591 New
AA
25
Ancora Advisors
Ohio
$192 – – –
1
2

LSBPW Hedge Fund Activity: Q4 2023 in Review

28 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q4 2023, worth a combined $266K — down 25% from $356K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of LSBPW and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $417. The largest seller was Ionic Capital Management, exiting entirely with an estimated $11.3K sold.

  • 28 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q4 2023, down from 30 in Q3 2023.
  • Funds reported $266K of LakeShore Biopharma Warrants stock for Q4 2023, down 25% quarter-over-quarter.
  • 2 funds opened new LakeShore Biopharma Warrants positions in Q4 2023 and 4 closed out, a net change of -2 holders.
  • The largest LakeShore Biopharma Warrants buyer in Q4 2023 was Susquehanna International Group, an estimated $417 added.
  • The largest LakeShore Biopharma Warrants seller in Q4 2023 was Ionic Capital Management, an estimated $11.3K sold.

Based on aggregated 13F filings for Q4 2023.